Logo for Alzinova

Alzinova Investor Relations Material

Latest events

Logo for Alzinova

Q1 2024

28 May, 2024
Logo for Alzinova

Q4 2023

28 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Alzinova

Access all reports
Alzinova AB, a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease. The lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers